[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583963":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":35,"centralContacts":39,"locations":48,"responsibleParty":68,"collaborators":71,"id":75,"slug":25,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":25,"enrollmentInfo":85,"targetDuration":25,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":25,"overallStatus":51,"whyStopped":25,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Varenicline","EXPERIMENTAL","Participants will be randomized 1:1 to varenicline or matched placebo. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1 mg b.i.d. starting on Day 8. Dosing of 2 mg per day will be maintained for the next 11 weeks.",[13,14,15],"Drug: Varenicline","Behavioral: Counseling","Behavioral: Psychosocial modules",{"label":17,"type":18,"description":19,"interventionNames":20},"Placebo","PLACEBO_COMPARATOR","Participants will be randomized 1:1 to varenicline or matched placebo.",[14,15],[22,26,31],{"type":23,"name":9,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG",[9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"BEHAVIORAL","Counseling","Research staff will provide skills-based counseling at weekly visits. Weekly counseling sessions will include discussion of online intervention modules, while providing skills-based strategies focused on enlisting social support, recognizing triggers, managing craving\u002Fwithdrawal\u002Fstress, etc. Staff will use motivational enhancement techniques to address tobacco cessation, cannabis reduction or abstinence, and medication adherence.",[17,9],{"type":27,"name":32,"description":33,"armGroupLabels":34,"otherNames":25},"Psychosocial modules","Participants will have access to online modules addressing tobacco and cannabis co-use to support cessation and\u002For reduction. Content includes 12 virtual modules combining cognitive behavioral therapy (CBT) and motivational enhancement (MET) to address tobacco, cannabis, and their co-use.",[17,9],[36],{"name":37,"affiliation":5,"role":38},"Erin Mcclure","PRINCIPAL_INVESTIGATOR",[40,44],{"name":37,"role":41,"phone":42,"phoneExt":25,"email":43},"CONTACT","843-792-7192","mccluree@musc.edu",{"name":45,"role":41,"phone":46,"phoneExt":25,"email":47},"Elizabeth Chapman","864-898-2992","chapmanb@musc.edu",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Medical University of South Carolina - Charleston","RECRUITING","Charleston","South Carolina","29403","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-79.93275,32.77632,{"lat":61,"lon":60},[64,65],{"name":45,"role":41,"phone":46,"phoneExt":25,"email":47},{"name":66,"role":41,"phone":25,"phoneExt":25,"email":67},"Ela Williams","williela@musc.edu",{"type":38,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Erin McClure","Associate Professor-Faculty",[72],{"name":73,"class":74},"National Cancer Institute (NCI)","NIH","100583963",false,"NCT06883162","Cannabis-Tobacco Co-Use Treatment Study","Randomized Controlled Trial of Varenicline to Treat Tobacco and Cannabis Co-Use (RECLAIM)","RECLAIM","Inclusion criteria:\n\n1. Ages 18 and over (no upper age limit)\n2. Must smoke at least 5 tobacco cigarettes per day on at least 20 out of the past 30 days for the past 3 months\n3. Must express interest in quitting tobacco\n4. Must express interest in cannabis reduction and\u002For cessation\n5. Must submit a positive instant-read test for cotinine and cannabis prior to enrollment\n6. Must self-report cannabis use (THC-dominant products) on at 3 days per week out of the past 30 days\n7. Must be willing to take varenicline or placebo for 12 weeks\n8. Must reside in South Carolina\n\nExclusion criteria:\n\n1. Any significant or acutely unstable medical, psychiatric, or substance use problem (including clinically significant disorders) that would contraindicate research, interfere with safety, compromise data integrity, or preclude consistent study participation\n2. Pregnant or trying to become pregnant\n3. Use of medications with smoking cessation efficacy\n4. Regular use of e-cigarettes or other tobacco products (\\\u003C10 days in the past month)",true,"ALL","18 Years",{"count":86,"type":87},200,"ESTIMATED","INTERVENTIONAL",[90],"PHASE3","The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence and cannabis reduction or abstinence. All participants will also receive counseling and access to online treatment modules during a quit attempt for cigarettes and a reduction attempt for cannabis. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed.\n\nTo qualify, participants must be 18 or older, live in South Carolina, use cigarettes and cannabis, and are interested in quitting cigarettes and reducing cannabis.",[93,94,95,96,97],"Tobacco Use Disorder","Tobacco Use Cessation","Cannabis Use","Cannabis Use Disorder","Marijuana Use","2026-04-02",{"date":100,"type":101},"2026-04-03","ACTUAL",{"date":103,"type":101},"2025-05-06",{"date":105,"type":87},"2029-01-01",{"name":5,"class":6},1]